MGDN (Video Update), BMY, LLL, RFX - Market Watch From PennyOmega.com!

Medgenics, Inc. (NYSE Amex:MDGN), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced that the Company received notice of ‘Intention to Grant’ from the European Patent Office for the patent application entitled “USE OF DERMAL MICRO ORGANS,� with allowed claims covering a core element of its Biopump™ protein therapy technology.

A counterpart patent in the United States was issued in December 2008, with rights extending to November 2023. The patent estate covering the Biopump includes compositions, methods of use and methods of manufacture, and includes issued patents in the United States, as well as pending applications in the United States and various foreign jurisdictions.

Medgenics is developing and commercializing Biopumpâ„¢, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.

******************************************

Bristol-Myers Squibb Company (NYSE:BMY) announced a donation of $6.9 million in 2011 to support the HealthWell Foundation, an independent non-profit organization that provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. The donation was made to HealthWell’s co-pay assistance funds to help underinsured cancer patients with their out-of-pocket disease related expenses that are not covered by their insurance plans, regardless of treatment selected.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

******************************************

L-3 Communications Holdings, Inc. (NYSE:LLL) announced that it intends to release its 2011 fourth quarter results on Tuesday, January 31, 2012 before the open of the market. In conjunction with this announcement, L-3 will host a conference call on the same day at 11:00 a.m. EST that will be simultaneously broadcast over the Internet. Michael T. Strianese, chairman, president and chief executive officer, and Ralph G. D’Ambrosio, senior vice president and chief financial officer, will host the call.

Headquartered in New York City, L-3 Communications employs approximately 61,000 people worldwide and is a prime contractor in C3ISR (Command, Control, Communications, Intelligence, Surveillance and Reconnaissance) systems, aircraft modernization and maintenance, and government services.

******************************************

Forest Laboratories, Inc. (NYSE:FRX) an international pharmaceutical manufacturer and marketer, announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012. Reported earnings per share in the third quarter of fiscal 2011 were $1.11 after a charge for a new product licensing fee of $66.1 million, or $0.23 per share net of tax, related to a licensing agreement with Grünenthal GmbH (Grünenthal) for GRT 6005 and its follow-on compound GRT 6006, for the treatment of moderate to severe chronic pain.

Forest Laboratories, longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory medicine.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.